Clinical Evaluation of dCELL® ACL Scaffold for Reconstruction of the Anterior Cruciate Ligament

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-09-30

Study Completion Date

2021-08-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The safety and performance of dCELL® ACL Scaffold will be evaluated in 40 patients who have been implanted with the investigational product following a ruptured anterior cruciate ligament (ACL) of the knee.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Evaluation of dCELL® Meniscus for Partial Replacement of the Meniscus

NCT02270905

Knee Injuries

SUSPENDED NA

Clinical Evaluation of a Resorbable PLLA Implant for Regeneration of the Anterior Cruciate Ligament (ACL)

NCT01634711

Complete Tear, Knee, Anterior Cruciate Ligament

COMPLETED PHASE1/PHASE2

Reconstruction of the Anterior Cruciate Ligament of the Knee Joint, by the Method of Stabilization of the Screw With a Bioabsorbable Method, With or Without the Use of Autogenous Spongiform Bone Grafts.

NCT05328544

Anterior Cruciate Ligament Injuries Anterior Cruciate Ligament Rupture Anterior Cruciate Ligament Tear +2 more

UNKNOWN NA

Triphasic Osteochondral Scaffold for the Treatment of the OCD of the Knee: Observational Study

NCT05332288

Osteochondritis Dissecans Knee

RECRUITING

Use of an Osteoconductive Scaffold in ACL-Reconstruction

NCT03462823

ACL - Anterior Cruciate Ligament Rupture ACL ACL Injury

ACTIVE_NOT_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The dCELL® ACL Scaffold is a novel device manufactured from porcine tissue using a patented variation of Tissue Regenix's platform technology to render the tissue biocompatible and free from cellular material, providing a biological scaffold that is safe for human implantation whilst preserving the biomechanical properties.

The device is used to reconstruct traumatic ACL tears to help restore normal knee function and therefore prevent further wear of the cartilage and future damage.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Knee Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

dCELL® ACL Scaffold

Group Type EXPERIMENTAL

dCELL® ACL Scaffold

Intervention Type DEVICE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

dCELL® ACL Scaffold

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with partial or complete tear of the ACL and require reconstruction of the ACL.
* Medial Collateral Ligament (MCL) injury grade 2 or less.
* Osteoarthritis grade 2 or less on the Kellgren Lawrence scale.
* Patients who have given written informed consent; and are willing and able to comply with entire study procedures including rehabilitation protocol.

Exclusion Criteria

* Body Mass Index (BMI) greater than 35 kg/m2.
* Treatment with any investigational drug or device within two months prior to screening.
* Patients presenting with abnormal degenerative osteoarthritis of the joint.
* Previous ACL reconstruction on the target knee.
* Current ACL injury on contralateral knee.
* Patients using anticoagulants within 2 weeks prior to surgery.
* Patients on current immuno-suppressive or radiation therapy within six months of screening.
* Patients with diabetes or cardiovascular disease which precludes elective surgery.
* Patients with documented renal disease or metabolic bone disease.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No